Malignant Female Reproductive System Neoplasm Clinical Trial
Official title:
Estudio Oportunidad: Optimizing Screening for Cervical Cancer Among Women Living With HIV in the Dominican Republic
Verified date | April 2024 |
Source | Fred Hutchinson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study compares different screening approaches to detect abnormal cell growth on the cervix that could be an early sign of cervical cancer. The lesions are caused by an infection of human papillomavirus, also called HPV. Using new methods to detect HPV may help doctors find ways to improve cervical cancer screening for women living with human immunodeficiency virus (HIV) in the Dominican Republic and in other countries.
Status | Active, not recruiting |
Enrollment | 619 |
Est. completion date | July 31, 2026 |
Est. primary completion date | July 31, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 25 Years to 49 Years |
Eligibility | Inclusion Criteria: - Women ages 25 - 49 years old will be eligible to participate in the study - Women and transgender men living with HIV who have an intact cervix - Intent to reside in the Santo Domingo area - Ability to attend routine study visits at IDCP for at least 24 months during the study. If women report that they anticipate relocating in the subsequent 24 months or anticipate difficulty attending study visits they will not be eligible - Ability to understand the study timeline and procedures and the willingness to complete the informed consent process are also inclusion criteria Exclusion Criteria: - Women with a prior diagnosis of cervical cancer or a history of treatment for cervical precancerous lesions (CIN2+) will be excluded - Women with significant physical, mental, or social conditions that would limit participation with study procedures will not be eligible for the study - Women who are pregnant or report an intent to become pregnant in the subsequent 3 months will not be eligible for the study - Women who have no history of vaginal sexual exposure will not be eligible for the study |
Country | Name | City | State |
---|---|---|---|
Dominican Republic | Instituto Dermatológico Dominicano y Cirugía de Piel (IDCP) "Dr. Huberto Bogaert Diaz" | Santo Domingo |
Lead Sponsor | Collaborator |
---|---|
Fred Hutchinson Cancer Center | Instituto Dermatológico Dominicano y Cirugía de Piel (IDCP), National Cancer Institute (NCI), US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet) |
Dominican Republic,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Detection of CIN2+ is improved by cervical imaging with automated visual evaluation that uses a machine learning algorithm vs colposcopy | Post hoc evaluation not impacting treatment decision comparing colposcopy to image score by Cohen's kappa using a scale of normal, precancer+ and greyzone/low grade using a coordinated scale | At baseline | |
Other | Assess overall burden of HPV disease | Prevalence of non-cervical visible lesions, histological confirmation of non-cervix lesions (at the vulva, vagina, and peri-anal region), and hrHPV testing status at the vagina and anal canal | At baseline | |
Primary | Detection of cervical precancerous lesions (CIN2+) by cytology vs HPV restricted genotyping | Compare performance characteristics of two screening strategies. Comparison between dichotomous tests will be summarized by: (i) the true positive rate (TPR) and (ii) the false positive rate (FPR). | At baseline | |
Secondary | Detection of cervical precancerous lesions (CIN3) by cytology vs HPV restricted genotyping | Compare performance characteristics of two screening strategies. Comparison between dichotomous tests will be summarized by: (i) the true positive rate (TPR) and (ii) the false positive rate (FPR). | At baseline | |
Secondary | Cross-sectional diagnostic accuracy of triage by dual staining among hrHPV positive WLWH to detect CIN2+ | Estimate the diagnostic accuracy parameters (TPR, FPR, positive predictive value or PPV, negative predictive value or NPV) and their approximate 95% confidence intervals for the p16/Ki-67 dual staining triage strategy for WLWH who tested positive for restricted hrHPV genotyping at Month 0. Will also assess and compare the accuracy parameters (TPR/FPR) of the dual staining method as it applies to hrHPV16 positive WLWH versus those who are positive for other types of hrHPV in two-sample (unpaired) comparisons of proportions (two-sample proportion tests). | At baseline | |
Secondary | Diagnostic accuracy of dual staining triage among hrHPV positive WLWH to detect CIN2+ by specimen collected and reading approach | Calculate (i) the Cohen's kappa and (ii) the concordance correlation coefficient to calculate agreement between the two methods. Use the McNemar test to compare the overall agreement between them. | At baseline | |
Secondary | Diagnostic accuracy of hrHPV genotyping to detect CIN2+ among WLWH by vaginal vs cervical sampling | Calculate (i) the Cohen's kappa and (ii) the concordance correlation coefficient to calculate agreement between the two methods. Use the McNemar test to compare the overall agreement between them. | At baseline | |
Secondary | CIN2+ Incidence | Estimate the cumulative incidence of newly detected CIN2+ over 2 years among women negative at previous time points. | At 12 and 24 months | |
Secondary | Detection of repeat CIN2+ | Calculate the proportion positive a second time for CIN2+ at Month 12 or 24. | At 12 and 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03968406 -
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
|
Phase 1 | |
Completed |
NCT01641068 -
Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms
|
N/A | |
Active, not recruiting |
NCT04266886 -
Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer
|
N/A | |
Active, not recruiting |
NCT01715168 -
A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT01356329 -
Efficacy and Safety of the LovenoxTM (Enoxaparin) Versus HeparinTM Gynecologic Oncology Patients
|
Phase 3 | |
Recruiting |
NCT06089083 -
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery
|
||
Completed |
NCT02518308 -
Mindfulness Intervention in Reducing Anxiety in Patients Who Have Been Treated for Gynecologic Cancer
|
N/A | |
Active, not recruiting |
NCT03776253 -
Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer
|
N/A | |
Recruiting |
NCT06126276 -
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
|
Phase 2 | |
Terminated |
NCT03345784 -
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
|
Phase 1 | |
Completed |
NCT01387841 -
Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting
|
Phase 2 | |
Completed |
NCT04269837 -
Sexual Health Counseling Intervention During Radiation Therapy in Improving Quality of Life for Women With Gynecologic Cancer
|
N/A | |
Completed |
NCT01433302 -
Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass
|
N/A | |
Completed |
NCT02423876 -
Epidural Anesthesia Within an Enhanced Recovery Pathway in Reducing Pain in Patients Undergoing Gynecologic Surgery
|
Phase 3 | |
Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
Completed |
NCT04456140 -
Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
|
Phase 1 | |
Terminated |
NCT02818530 -
Correlation Between Intraocular Pressure Measurement by Tomometer and Anterior Chamber Depth Measurement by Ultrasound
|
N/A | |
Recruiting |
NCT05786456 -
e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study
|
N/A | |
Recruiting |
NCT05625360 -
REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss
|
Phase 3 | |
Completed |
NCT04258631 -
Liposomal Bupivacaine With or Without Hydromorphone for the Improvement of Pain Control After Laparotomy in Patients With Gynecological Malignancies
|
Phase 4 |